Bristol Myers’ Phase 3 RELATIVITY-098 for Opdualag did not meet primary endpoint
Bristol Myers Squibb announced the Phase 3 RELATIVITY-098 trial evaluating Opdualag (nivolumab and relatlimab-rmbw) for the adjuvant treatment of patients wi ...
Agentic AI Startup Eudia Raises $105M, With Backing From Former Relativity CEOs
The startup’s augmented intelligence platform uses AI agents to streamline a variety of tasks for chief legal officers and in ...
Cellebrite Announces Fourth-Quarter and Full-Year 2024 Results
Company delivers “Rule of 50” Performance in 2024 with 25% ARR growth and 25% adjusted EBITDA marginFourth-quarter 2024 revenue of $109.0 million ...
Adobe Launches Contract Intelligence Capabilities in Its Acrobat AI Assistant
On Feb. 4, software company Adobe announced new contract intelligence capabilities in its Acrobat AI Assistant that ...